1346555-41-6

Basic information

• Product Name: (R)-tert-butyl 2-(2-methyl-4-(4-(methylsulfonyl)phenyl)piperazin-1-yl)pyrimidine-4-carboxylate
• Synonyms: (R)-tert-butyl 2-(2-methyl-4-(4-(methylsulfonyl)phenyl)piperazin-1-yl)pyrimidine-4-carboxylate
• CAS NO: 1346555-41-6
• Molecular Weight: 432.544
• Mol File: 1346555-41-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (R)-tert-butyl 2-(2-methyl-4-(4-(methylsulfonyl)phenyl)piperazin-1-yl)pyrimidine-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-tert-butyl 2-(2-methyl-4-(4-(methylsulfonyl)phenyl)piperazin-1-yl)pyrimidine-4-carboxylate(1346555-41-6)
• EPA Substance Registry System: (R)-tert-butyl 2-(2-methyl-4-(4-(methylsulfonyl)phenyl)piperazin-1-yl)pyrimidine-4-carboxylate(1346555-41-6)

Safety Data

• Hazardous Substances Data: 1346555-41-6(Hazardous Substances Data)

Upstream product

• 942474-66-0 (3R)-3-methyl-1-[4-(methylsulfonyl)phenyl]piperazine 
• 220041-42-9 tert-butyl 2-chloropyrimidine-4-carboxylate 
• 149849-92-3 2‐chloropyrimidine‐4‐carboxylic acid 

Relevant articles and documents

PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHAMACEUTICAL COMPOSITION COMPRISING THE SAME

Provided are picolinamide and pyrimidine-4-carboxamide compounds, a method for preparing the same, a pharmaceutical composition containing the same, and a medical use using the compound as an agent for preventing, regulating, and treating diseases related to regulation of glucocorticoids by using selective inhibitory activity of the compound for an 11β-HSD1 enzyme. The picolinamide and pyrimidine-4-carboxamide compounds of the present invention are selective inhibitors of human-derived 11β-HSD1 enzymes, and are useful in an agent for preventing, regulating, and treating diseases related to glucocorticoid regulation in which human- derived 11β-HSD1 enzymes are involved, for example, metabolic syndromes such as, type 1 and type 2 diabetes, diabetes later complications, latent autoimmune diabetes adult (LAD A), insulin tolerance syndromes, obesity, impaired glucose tolerane (IGT), impaired fasting glucose (IFG), damaged glucose tolerance, dyslipidemia, atherosclerosis, hypertension, etc.